征祥医药港股IPO：唯一商业化产品面临医保、仿制药、先行者三重压力 上市前夕董事会“大换血”

Core Viewpoint - Zhengxiang Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative therapies for viral infections, tumors, and inflammatory diseases. However, the company faces significant challenges, including substantial losses and intense competition in the market for its core product, which may hinder its path to a successful IPO [1][11]. Financial Performance - The company has reported cumulative losses exceeding 400 million RMB over the past three years, with a net loss of 145 million RMB in the first three quarters of 2025, indicating no signs of improvement [2][12]. - Revenue for 2024 is projected to be zero, with only 3.55 million RMB generated in the first nine months of 2025, all from providing drug registration assistance to an overseas partner [2][12]. - As of September 30, 2025, the company had cash and cash equivalents of 118 million RMB, with total available funds around 270 million RMB, which could sustain operations for approximately 30 months at the current cash burn rate [2][12]. Asset and Liability Situation - As of September 30, 2025, the company reported total current assets of 292 million RMB and total current liabilities of 1.195 billion RMB, resulting in a net current liability of 903 million RMB, an increase of 18.7% from the end of 2024 [3][13]. - The overall debt-to-asset ratio has risen to 415.84%, with redemption liabilities amounting to 1.092 billion RMB, primarily from previous financing commitments [3][13]. Market Competition - Zhengxiang Pharmaceutical's core product, Marcilosavir, faces fierce competition from established players, including Roche's Mabalaosavir, which has seen a 180% increase in sales in 2025, surpassing 2 billion RMB [6][16]. - The pricing of Marcilosavir at 222 RMB per box is higher than domestic competitors, which may limit its market penetration, especially since it was not included in the 2025 national medical insurance directory [6][16]. Governance and Management Issues - The company exhibits a highly centralized governance structure, with the founder serving as both chairman and CEO, which may weaken the board's independent oversight [9][19]. - A significant turnover in the board and senior management, with 13 directors leaving around the time of the listing application, raises concerns about stability and strategic alignment [9][19]. - The ownership structure is fragmented, with the founding team holding only 22.76% of voting rights, potentially complicating decision-making processes in future financing or mergers [10][20].